Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692162 | 0.84 | CA2 (0.36) | TSHR | |
| SCHEMBL22336 | 0.81 | MAOB (0.43) | TSHRMAPK1HTT | |
| SCHEMBL1559901 | 0.80 | ALDH1A1 (0.42) | GAAMAPTTSHRHTT | |
| SCHEMBL1277500 | 0.78 | ALDH1A1 (0.38) | GAAMAPTTSHR | |
| SCHEMBL18580455 | 0.78 | ALDH1A1 (0.46) | TSHR | |
| SCHEMBL16687408 | 0.77 | PDCD1 (0.47) | PDCD1CD274PDE4APDE4BPDE4C | |
| SCHEMBL473910 | 0.76 | KDM4E (0.37) | GAAMAPTMAPK1HTT | |
| SCHEMBL16346292 | 0.76 | TNFSF11 (0.41) | GAAMAPTTSHRMAPK1 | |
| SCHEMBL9894132 | 0.76 | NR3C1 (0.47) | GAAMAPTTSHR | |
| SCHEMBL6696220 | 0.76 | RIPK1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932360-B2 | Qualitative and quantitative point-of-care assays | THE PENN STATE RESEARCH FOUNDATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9200131-B2 | Organic acid-modified polymers for golf ball constructions and methods relating thereto | ACUSHNET COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150005193-A1 | QUALITATIVE AND QUANTITATIVE POINT-OF-CARE ASSAYS | NATIONAL SCIENCE FOUNDATION | 2015-01-01 | — | — | US | disclosed |
| US-20150005101-A1 | ORGANIC ACID-MODIFIED POLYMERS FOR GOLF BALL CONSTRUCTIONS AND METHODS RELATING THERETO | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005193-A1 | QUALITATIVE AND QUANTITATIVE POINT-OF-CARE ASSAYS | CUTA, AQP4, CD63 | PDCD1 1701/4885CD274 1005/4885PDE4A 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.